COPENHAGEN, Nov 30 (Reuters) - Denmark’s Novo Nordisk (NOVOb.CO: Quote, Profile, Research), the world’s biggest maker of insulin, plans to expand its sales force for diabetes care from 1,200 to about 1,900 people in the United States in the first half of 2007, an increase of nearly 60 percent. The company said on Thursday the move was designed to strengthen its position in a key growth market.
